Kennedy Capital Management Inc. raised its stake in shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) by 0.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 293,042 shares of the company’s stock after purchasing an additional 593 shares during the period. Kennedy Capital Management Inc. owned 0.13% of Endo International PLC worth $3,273,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in the business. Jensen Investment Management Inc. grew its holdings in Endo International PLC by 24.2% during the second quarter. Jensen Investment Management Inc. now owns 30,620 shares of the company’s stock valued at $342,000 after purchasing an additional 5,960 shares during the last quarter. River & Mercantile Asset Management LLP acquired a new position in Endo International PLC during the second quarter valued at approximately $1,851,000. Airain ltd acquired a new position in Endo International PLC during the second quarter valued at approximately $387,000. Point View Wealth Management Inc. grew its stake in shares of Endo International PLC by 16.6% in the second quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock worth $149,000 after acquiring an additional 1,900 shares during the last quarter. Finally, Blair William & Co. IL acquired a new stake in shares of Endo International PLC in the second quarter worth $126,000. Institutional investors own 90.71% of the company’s stock.
In other Endo International PLC news, CFO Blaise Coleman acquired 6,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was acquired at an average cost of $7.89 per share, for a total transaction of $51,285.00. Following the transaction, the chief financial officer now directly owns 13,729 shares in the company, valued at $108,321.81. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Terrance J. Coughlin acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were acquired at an average price of $7.70 per share, with a total value of $154,000.00. Following the completion of the transaction, the chief operating officer now owns 181,369 shares in the company, valued at $1,396,541.30. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 36,000 shares of company stock valued at $279,460. 0.50% of the stock is owned by corporate insiders.
Several equities research analysts have recently issued reports on the stock. Piper Jaffray Companies restated a “hold” rating and issued a $9.00 price objective on shares of Endo International PLC in a research note on Sunday. Royal Bank Of Canada set a $9.00 price objective on shares of Endo International PLC and gave the stock a “hold” rating in a research note on Thursday, August 10th. Cowen and Company restated a “hold” rating and issued a $16.00 price objective on shares of Endo International PLC in a research note on Thursday, August 10th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Endo International PLC in a research note on Tuesday, August 8th. Finally, Guggenheim assumed coverage on shares of Endo International PLC in a research note on Saturday, June 17th. They issued a “hold” rating and a $12.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $14.33.
Endo International PLC (ENDP) opened at 8.60 on Monday. The company has a 50 day moving average price of $8.88 and a 200-day moving average price of $10.89. The company’s market capitalization is $1.92 billion. Endo International PLC has a 12-month low of $7.41 and a 12-month high of $23.98.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.19. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The business had revenue of $875.73 million during the quarter, compared to the consensus estimate of $832.66 million. During the same period in the prior year, the company earned $0.86 EPS. Endo International PLC’s revenue for the quarter was down 4.9% on a year-over-year basis. On average, analysts anticipate that Endo International PLC will post $3.52 EPS for the current year.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.